Inarigivir soproxil

DRUG4 trials

Sponsors

Gilead Sciences, F-star Therapeutics, Inc.

Conditions

Chronic Hepatitis BHBVHepatitis BHepatitis B, Chronic

Phase 2

Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)

TerminatedNCT03434353

Gilead SciencesChronic Hepatitis B

Start: 2018-02-28End: 2021-01-26Updated: 2022-04-04

Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B Patients

TerminatedNCT03932513

F-star Therapeutics, Inc.HBV, Hepatitis B, Hepatitis B, Chronic

Start: 2019-04-11End: 2019-12-21Updated: 2020-04-29

Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor

TerminatedNCT04023721

F-star Therapeutics, Inc.HBV, Hepatitis B, Hepatitis B, Chronic

Start: 2019-06-18End: 2020-07-16Updated: 2020-07-22

Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus

TerminatedNCT04059198

F-star Therapeutics, Inc.HBV, Hepatitis B, Hepatitis B, Chronic

Start: 2019-10-10End: 2020-04-02Updated: 2020-07-21